Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)

NCT03223103 is registered in ClinicalTrials.gov with Adilia Hormigo as lead sponsor.

NCT NCT03223103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03223103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)
Lead sponsor
Adilia Hormigo
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 1, 2018
Completion date
May 12, 2029
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma